B
RARE icon

Baird’s Ultragenyx Pharmaceutical RARE Stock Holding History

Baird’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-4,222
Closed -$239K – 1311
2014
Q3 		$239K Buy
+4,222
New +$212K ﹤0.01% 1023

Other funds holding RARE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Baird's RARE Position: Q4 2014 in Review

Baird sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2014, closing a stake of 4,222 shares — an estimated $239K sold.

Baird first reported a position in RARE in Q3 2014 and held it in 1 quarter. The position peaked at $239K in Q3 2014. 100 funds tracked by Wall St. Rank hold RARE as of Q4 2014.

  • Baird reported no remaining Ultragenyx Pharmaceutical position as of Q4 2014 after selling out during the quarter.
  • Baird sold 4,222 Ultragenyx Pharmaceutical shares in Q4 2014, an estimated $239K.
  • Baird first reported a position in Ultragenyx Pharmaceutical in Q3 2014 and held it in 1 quarter.
  • Baird's Ultragenyx Pharmaceutical position peaked at $239K in Q3 2014.
  • 100 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2014.

Based on Baird's 13F filing for Q4 2014, filed 12 Feb 2015.